The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
复制标题
静脉输铁羧化合物对急性心力衰竭患者与健康相关的生活质量生活质量的影响：肯定AHF研究的结果。
DOI：
10.1093/eurheartj/ehab234
复制
发表时间：
2021-08-17
影响因子：
39.3
通讯作者：
Ponikowski P
中科院分区：
文献类型：
--
作者：
Jankowska EA;Kirwan BA;Kosiborod M;Butler J;Anker SD;McDonagh T;Dorobantu M;Drozdz J;Filippatos G;Keren A;Khintibidze I;Kragten H;Martinez FA;Metra M;Milicic D;Nicolau JC;Ohlsson M;Parkhomenko A;Pascual-Figal DA;Ruschitzka F;Sim D;Skouri H;van der Meer P;Lewis BS;Comin-Colet J;von Haehling S;Cohen-Solal A;Danchin N;Doehner W;Dargie HJ;Motro M;Friede T;Fabien V;Dorigotti F;Pocock S;Ponikowski P
患有心力衰竭(HF)和铁缺乏的患者的健康相关生活质量(HRQOL)较低。我们评估了静脉注射(IV)羧基麦芽糖(FCM)与安慰剂对确诊AHF人群的HRQL的影响。在随机化之前以及第2、4、6、12、24、36和52周，分别对FCM组和安慰剂组中的1058名(和523名)患者完成了基线12项堪萨斯城心肌病问卷(KCCQ-12)。基线KCCQ-12总分(OSS)平均 ± 标准误分别为38.7FCM组和37.1FCM组和37.1 ± 0.8，临床总分的对应值分别为40.9 ± 0.9和40.1 ± 0.9。在第2周，FCM组和安慰剂组OSS和CS的变化相似。从第4周到第24周，与安慰剂相比，接受FCM治疗的患者在OSS和CSs评分上有显著改善[调整后的平均差值(95%可信区间，CI)：OSS2.9(0.55.3，P=0.018)和CS2.8(0.35.3，P=0.029)；24周调整后平均差(95%CI)：OSS组为3.0%(0.30-5.6P=0.028)，CS组为2.9%(0.2%-5.6P=0.035)。在52周时，治疗效果有所减弱，但仍有利于FCM。与安慰剂相比，在急性心力衰竭发作后稳定下来的铁缺乏的心力衰竭患者中，左心室射血分数<50%的患者，与安慰剂相比，在治疗开始后4周就对HRQL产生了临床上有意义的有益影响，一直持续到24周。
Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for the AFFIRM-AHF population. The baseline 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which was completed for 1058 (535 and 523) patients in the FCM and placebo groups, respectively, was administered prior to randomization and at Weeks 2, 4, 6, 12, 24, 36, and 52. The baseline KCCQ-12 overall summary score (OSS) mean ± standard error was 38.7 ± 0.9 (FCM group) and 37.1 ± 0.8 (placebo group); corresponding values for the clinical summary score (CSS) were 40.9 ± 0.9 and 40.1 ± 0.9. At Week 2, changes in OSS and CSS were similar for FCM and placebo. From Week 4 to Week 24, patients assigned to FCM had significantly greater improvements in OSS and CSS scores vs. placebo [adjusted mean difference (95% confidence interval, CI) at Week 4: 2.9 (0.5–5.3, P = 0.018) for OSS and 2.8 (0.3–5.3, P = 0.029) for CSS; adjusted mean difference (95% CI) at Week 24: 3.0 (0.3–5.6, P = 0.028) for OSS and 2.9 (0.2–5.6, P = 0.035) for CSS]. At Week 52, the treatment effect had attenuated but remained in favour of FCM. In iron-deficient patients with HF and left ventricular ejection fraction <50% who had stabilized after an episode of acute HF, treatment with IV FCM, compared with placebo, results in clinically meaningful beneficial effects on HRQoL as early as 4 weeks after treatment initiation, lasting up to Week 24.
登录
查看更多内容
影响因子：
8.9
作者：
Lewis, EF;Johnson, PA;Stevenson, LW
通讯作者：
Stevenson, LW
影响因子：
37.8
作者：
Kosiborod, Mikhail N.;Jhund, Pardeep S.;McMurray, John J. V.
通讯作者：
McMurray, John J. V.
DOI：
10.1161/circoutcomes.115.001958
发表时间：
2015-09-01
影响因子：
6.9
作者：
Spertus, John A.;Jones, Philip G.
通讯作者：
Jones, Philip G.
影响因子：
18.2
作者：
Ponikowski, Piotr;Kirwan, Bridget-Anne;Jankowska, Ewa A.
通讯作者：
Jankowska, Ewa A.
影响因子：
39.3
作者：
Butler J;Anker SD;Filippatos G;Khan MS;Ferreira JP;Pocock SJ;Giannetti N;Januzzi JL;Piña IL;Lam CSP;Ponikowski P;Sattar N;Verma S;Brueckmann M;Jamal W;Vedin O;Peil B;Zeller C;Zannad F;Packer M;EMPEROR-Reduced Trial Committees and Investigators
通讯作者：
EMPEROR-Reduced Trial Committees and Investigators